My watch list  


Atripla® is a fixed dose combination drug for the treatment of HIV infection. It combines Gilead Sciences's tenofovir and emtricitabine (already available in the anti-HIV combination Truvada®) with Bristol-Myers Squibb's efavirenz into a fixed-dose pill. Combining the three drugs into a single, once-daily pill reduces pill burden and simplifies dosing schedules, and therefore has the potential to increase adherence to antiretroviral therapy.

Atripla is the first multi-class antiretroviral drug available in the United States and represents the first collaboration between two U.S. pharmaceutical companies to combine their patented anti-HIV drugs into one product. The drug costs approximately $1,150 USD for a one-month supply. As of 2007, in India it costs $1,344 USD per year and in Africa $528 USD. It was approved by the U.S. FDA on July 12 2006.

Atripla is a fixed dose combination of 600 mg Efavirenz, 300 mg Tenofovir, and 200 mg Emtricitabine. In adults, it is taken once daily on an empty stomach. Dosing at bedtime is recommended to improve tolerability of nervous system symptoms. Atripla is not recommended for patients under 18 years of age.

Atripla is a pink, capsule-shaped tablet with "123" impressed on one side.

In North America and Europe, Atripla is marketed jointly by Gilead Sciences and Bristol-Myers Squibb, but in much of the developing world, marketing and distribution is handled by Merck & Co.[1] In India, Cipla has released its own copy of Atripla, called Viraday.


  1. ^ Merck to Register Lower Cost of Antiretroviral Atripla in Developing Countries

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Atripla". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE